Horizon Establishes Two New Centers of Excellence in Cambridge, UK
News Jun 18, 2013
Horizon Discovery has announced that it has established two new Centers of Excellence (CoEs) for gene editing in Cambridge, UK.
The new Centers are at the Gurdon Institute, Cambridge University with Prof. Steve Jackson FRS, and the Cambridge Institute for Medical Research with Prof. David Rubinsztein.
Prof. Jackson aims to establish Horizon’s rAAV genome editing technology (GENESIS™) as a core technology within his lab at the Gurdon Institute for generating isogenic cell models of cancer.
They will focus on generating cell lines with specific mutations in genes involved in DNA repair and DNA damage signaling, to study their relationship to cancer progression.
Prof. Rubinsztein’s lab will apply GENESIS to generate isogenic cell line models for the study of autophagy (degradation of unnecessary or dysfunctional cellular components), which has been a focus since their discovery that autophagy regulates the levels a set of specific proteins that cause many neurodegenerative diseases.
“The increasing number of research groups of this caliber working with our genome editing technology is very exciting for Horizon,” said Dr Rob Howes, Principal Scientist, Horizon.
Dr Howes continued, “We are delighted to welcome both the Gurdon Institute and Cambridge Institute for Medical Research to our Centers of Excellence network and look forward to working with them on developing the cell lines.”
The new human isogenic cell lines generated by the CoEs will be exclusively licensed to Horizon in return for future product royalties.
Horizon will also have an exclusive option to license new intellectual property developed. This forms part of Horizon’s strategy to generate at least 2,500 new X-MAN™ (gene X- Mutant And Normal) models of cancer, neurodegenerative, and cardiovascular disease.
These models support drug discovery researchers in their efforts to understand how complex genetic diseases manifest themselves in real patients, and help rationalize many aspects of drug development, reducing the cost of bringing to market new personalized therapies.
These centers become part of the larger Horizon Centers of Excellence network, which includes high profile Institutions such as UCL, Yale University, the National Cancer Institute, Washington University in St Louis and the National Cancer Centre, Japan.
Horizon sponsors an online community portal, www.rAAVers.org, for scientists working with rAAV-mediated and other forms of genome editing.
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE